Literature DB >> 20554750

Killing the killer: natural killer cells to treat Ewing's sarcoma.

Yong-Oon Ahn1, Brenda Weigel, Michael R Verneris.   

Abstract

Cho and coworkers show that Ewing's sarcoma cells are highly sensitive to expanded allogeneic natural killer (NK) cells, partially through a NKG2D- and DNAM-1-dependent mechanism. Using an orthotopic murine model, they also show that irradiation significantly enhances the NK-cell killing of these tumors. (c) 2010 AACR.

Entities:  

Mesh：

Year:  2010        PMID： 20554750      PMCID： PMC5659354          DOI： 10.1158/1078-0432.CCR-10-1368

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  7 in total

1.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

2.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.

Authors:  Stephan Gasser; Sandra Orsulic; Eric J Brown; David H Raulet
Journal:  Nature       Date:  2005-07-03       Impact factor: 49.962

3.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

Review 4.  Prospects for the use of NK cells in immunotherapy of human cancer.

Authors:  Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

5.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.

Authors:  Hiroyuki Fujisaki; Harumi Kakuda; Noriko Shimasaki; Chihaya Imai; Jing Ma; Timothy Lockey; Paul Eldridge; Wing H Leung; Dario Campana
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

6.  ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.

Authors:  Alessandra Soriani; Alessandra Zingoni; Cristina Cerboni; Maria Luisa Iannitto; Maria Rosaria Ricciardi; Valentina Di Gialleonardo; Marco Cippitelli; Cinzia Fionda; Maria Teresa Petrucci; Anna Guarini; Robin Foà; Angela Santoni
Journal:  Blood       Date:  2008-12-19       Impact factor: 22.113

7.  NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.

Authors:  Dirk H J Verhoeven; Alfons S K de Hooge; Esther C K Mooiman; Susy Justo Santos; Monique M ten Dam; Hans Gelderblom; Cornelis J M Melief; Pancras C W Hogendoorn; R Maarten Egeler; Maarten J D van Tol; Marco W Schilham; Arjan C Lankester
Journal:  Mol Immunol       Date:  2008-07-26       Impact factor: 4.407
  7 in total
  9 in total

1.  Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.

Authors:  P Schlegel; T Feuchtinger; C Nitschke-Gérard; U J Eva Seidel; A-M Lang; C Kyzirakos; H-M Teltschik; M Ebinger; M Schumm; E Koscielniak; R Handgretinger; P Lang
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

2.  Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.

Authors:  Kristin Baird; Terry J Fry; Seth M Steinberg; Michael R Bishop; Daniel H Fowler; Cynthia P Delbrook; Jennifer L Humphrey; Alison Rager; Kelly Richards; Alan S Wayne; Crystal L Mackall
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-05       Impact factor: 5.742

3.  Targeted Therapy of Ewing's Sarcoma.

Authors:  Vivek Subbiah; Pete Anderson
Journal:  Sarcoma       Date:  2010-10-31

Review 4.  3D tissue-engineered model of Ewing's sarcoma.

Authors:  Salah-Eddine Lamhamedi-Cherradi; Marco Santoro; Vandhana Ramammoorthy; Brian A Menegaz; Geoffrey Bartholomeusz; Lakesla R Iles; Hesham M Amin; J Andrew Livingston; Antonios G Mikos; Joseph A Ludwig
Journal:  Adv Drug Deliv Rev       Date:  2014-08-07       Impact factor: 15.470

5.  Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma.

Authors:  Alexander A Tong; Hasan Hashem; Saada Eid; Frederick Allen; Daniel Kingsley; Alex Y Huang
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

6.  NSG Mice Facilitate ex vivo Characterization of Ewing Sarcoma Lung Metastasis Using the PuMA Model.

Authors:  Renata Scopim-Ribeiro; Michael M Lizardo; Hai-Feng Zhang; Anne-Chloé Dhez; Chistopher S Hughes; Poul H Sorensen
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

7.  Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.

Authors:  Dagmar Berghuis; Marco W Schilham; Hanneke I Vos; Susy J Santos; Stephan Kloess; Emilie P Buddingh'; R Maarten Egeler; Pancras Cw Hogendoorn; Arjan C Lankester
Journal:  Clin Sarcoma Res       Date:  2012-02-08

8.  Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.

Authors:  Chihab Klose; Susanne Berchtold; Marina Schmidt; Julia Beil; Irina Smirnow; Sascha Venturelli; Markus Burkard; Rupert Handgretinger; Ulrich M Lauer
Journal:  BMC Cancer       Date:  2019-12-03       Impact factor: 4.430

Review 9.  A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.

Authors:  Zili Lin; Ziyi Wu; Wei Luo
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.